Bioxcel therapeutics announces phase 3 trials results of bxcl501 for treatment of agitation in patients with schizophrenia and bipolar disorder

Bioxcel therapeutics announces primary and secondary endpoints met in two pivotal phase 3 trials of bxcl501 for the acute treatment of agitation in patients with schizophrenia and bipolar disorder.bioxcel therapeutics inc - bxcl501 was well tolerated with no serious adverse events.bioxcel therapeutics inc - all exploratory endpoints demonstrated statistically significant in bxcl501 study.bioxcel therapeutics inc - nda submission to u.s. food and drug administration planned for q1 2021 for bxcl501.bioxcel therapeutics - is also exploring potential of bxcl501 in other hyperarousable disease states.
BTAI Ratings Summary
BTAI Quant Ranking